Antibody-Drug Conjugate Development
ImmunoGen Signs $220M TAP Deal with Eli Lilly
ImmunoGen Inc. licensed its maytansinoid targeted antibody payload (TAP) technology to Eli Lilly and Co., for the development of a limited number of antibody-drug conjugates for cancer. Lilly will pay $20 million up front and up to $200 million in milestone payments. ImmunoGen will also receive compensation for any research and manufacturing services it may provide to Lilly.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.